Research into multiple myeloma is progressing rapidly. In particular, a bispecific antibody targeting BCMA is being tested in the US for the treatment of refractory cases. Furthermore, recent studies, such as EXCALIBER-RRMM in the US and a multi-center study in Asia, are exploring the relationship between MRD negativity and survival in patients with refractory multiple myeloma.
Made by MielomaAI On November 17, 2026, at 11:43, based on recent news. May contain errors. View news →
In the last 3 months. On the site you’ll find the news from the last 3 months. The older ones only have the title and a link, in file by topicsIt’s a support website for people with multiple myeloma. It aims to keep things simple and clear. MielomaAI As you may find.
Collected from Portuguese newspapers, Google News (PT, EN, ES, FR) and associations and scientific societies. They are on the website 197 news: only from the last 3 months. The older ones are only shown with the title and link, in file by topicsAnd research and the MielomaAI You continue to find them. Always consult the original news article and speak with your doctor before drawing conclusions about your case. Last update: November 17, 2026, 3:21 PM.
Monday, 16/11
Etentamig in Relapsed/Refractory Multiple Myeloma: Pooled Phase 1 Data of an Investigational BCMA Bispecific AntibodyNational Institutes of Health (NIH) | (.gov) (EUA) · 23:37 InvestigaçãoEUA
Thursday, November 12th
Impressive Results of Trispecific Antibody in Myeloma Presented at EHA 2025 CongressTargeted Onc (EUA) · 22:00 InvestigaçãoEUARecent advancements in multiple myeloma treatment highlight the promise of trispecific antibodies like JNJ-5322, potentially enhancing patient outcomes significantly.
What Sustained MRD Negativity Can Settle About Stopping Myeloma MaintenanceCancerNetwork (EUA) · 21:08 InvestigaçãoEUASaad Z. Usmani, MD, MBA, FACP, FASCO, discussed the threshold he will act on in standard-risk disease, and the trial that would make the decision firmer.
EXCALIBER-RRMM Trial Results: MRD Negativity and Progression-Free Survival in Relapsed/Refractory Multiple MyelomaCancerNetwork (EUA) · 13:13 InvestigaçãoEUAIn this segment, Dr. Joseph Mikhael and Dr. Paul Richardson discuss findings from the phase 3 EXCALIBER-RRMM trial, which compared iberdomide plus daratumumab and dexamethasone with bortezomib plus daratumumab and dexamethasone in patients with relapsed/refractory multiple myeloma.
Wednesday, 11/11
Mehak Trehan: 10 Pivotal Myeloma Abstracts to Watch at ASH 2026Oncodaily (EUA) · 19:13 InvestigaçãoEUAMehak Trehan: 10 Pivotal Myeloma Abstracts to Watch at ASH 2026 / ASH 2026, cancer care, Cancer research, Hematology, Mehak Trehan, Myeloma, OncoDaily
Tuesday, November 3rd
Evidence Supporting MRD Negativity as a Prognostic and Regulatory Endpoint in Multiple MyelomaCancerNetwork (EUA) · 08:00 InvestigaçãoEUAIn this segment, Dr. Joseph Mikhael asks Dr. Scott Goldsmith to explain the evidence supporting the use of minimal residual disease (MRD) negativity as an endpoint for regulatory decision-making in multiple myeloma.
MRD Negativity and Its Clinical Significance in Multiple MyelomaCancerNetwork (EUA) · 08:00 InvestigaçãoEUAIn this segment, Dr. Joseph Mikhael, Dr. Paul Richardson, and Dr. Scott Goldsmith introduce the relationship between minimal residual disease (MRD) negativity and cereblon E3 ligase modulators (CELMoDs) in multiple myeloma, highlighting the role of MRD-negative complete response as an emerging regulatory endpoint.
Imaging the Invisible: A New Precision Approach to Detecting Multiple MyelomaUniversity of Miami (EUA) · 08:00 InvestigaçãoEUAA phase 2 Sylvester trial found that CD38-targeted immunoPET can reveal active multiple myeloma missed by standard PET/CT.
